Etanercept
Indication
Juvenile Idiopathic Arthritis (JIA) in Adult Patients
Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis NICE TA373
Red
Brand:
Enbrel ®, Benepali®
Nice TA:
373
Commissioning responsibility:
CCG
PbR excluded:
Yes
BNF chapter:
Musculoskeletal system
Background
Treatment with Etanercept for adult patients with JIA is recommended in Lancashire and South Cumbria in the following circumstances:
-
Young people with JIA currently being treated with one of the agents within the LSCMMG position statement and transferring over from adolescent to adult services
-
Patients with JIA whose disease becomes active during adult life
-
Patients with JIA requiring a biologic agent to be reinstated (e.g. after a period of remission or pregnancy)
In the above circumstances treatment is only recommended if the following criteria are met:
Treatment was in line with NICE TA373 before transfer to adult services OR is in line with NICE TA373 (with the exception of any age restrictions) for newly treated patients. For continuation into adulthood, if treatment was not in line with a NICE TA, the patient may continue to receive treatment until the prescribing clinician feels this may be stopped.
Recommendation
LSCMMG Recommendation:
Red
Reason for decision:
Specialist medicine
Supporting documents: